MOUNTAIN VIEW, Calif., April 22 /PRNewswire-FirstCall/ -- Alexza
Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it will host a
live audio webcast of presentations given at the Company's Investor and
Analyst Day on Tuesday, April 29th, 2008. Leading medical experts will
discuss the Phase 1 and Phase 2 results of the Company's clinical trials,
provide an overview of the Phase 3 trial design for AZ-004 (Staccato(R)
loxapine), and discuss the role that AZ-004 may play in treating acute
agitation in schizophrenic or bipolar disorder patients. Alexza senior
management will also provide an overview of Alexza's other clinical stage
What: Presentations (Audio & Slides)
Who: Dr. Michael Allen - University of Colorado Health Sciences
Associate Professor of Psychiatry
Director, Emergency and Consultation Psychiatry
Co-Director, Mood Disorders Program
Past President and Trustee, American Association for
Dr. Carol Tamminga -- University of Texas Southwestern
Professor of Psychiatry
Vice Chair for Clinical Research
Chief of Translational Neuroscience Research in
Communities Foundation of Texas Chair in Brain Science
When: Tuesday, April 29th, 2008 at 12:15-3:00 p.m. EDT
How: Live over the Internet -- Simply log on to the Web at the
address above and register for the event (approximately 10
If you are unable to participate during the live webcast, the call will be archived on Alexza's website at http://www.alexza.com.
About Alexza Pharmaceuticals
Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.
Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates in Phase 1 testing include AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza is available online at http://www.alexza.com.
Safe Harbor Statement
The anticipated webcast and presentations will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission, including the risks under the headings. Forward-looking statements contained in the webcast and presentations are made as of their date of presentation, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
|SOURCE Alexza Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved